Quantel Medical launches breakthrough SubCyclo laser procedure for treatment of glaucoma

Quantel Medical launches breakthrough SubCyclo laser procedure for treatment of glaucoma

Quantel Medical launches breakthrough SubCyclo laser procedure for treatment of glaucoma

Quantel Medical (Quantel), a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases, today announced the launch of the SubCyclo™ laser procedure at the World Glaucoma Congress (WGC 2017) meeting being held in Helsinki, Finland, June 28 – July 1. The SybCyclo laser procedure is a safe and effective treatment for primary open-angle glaucoma and angle-closure glaucoma.

Glaucoma is a group of eye diseases that develop due to elevated intraocular pressure (IOP), which can affect the optic nerve and cause vision loss. According to the World Health Organization, glaucoma affects more than 65 million people worldwide and is the second leading cause of legal blindness. Thermal transscleral cyclophotocoagulation is an effective treatment for glaucoma that reduces production of aqueous humor in the eye’s ciliary body, lowering IOP. However, because it is a destructive procedure associated with side effects and complications, it is recommended only for patients with refractory glaucoma for whom previous treatments have failed.

SubCyclo is a novel non-thermal glaucoma treatment based on the transscleral cyclophotocoagulation principle. The procedure lowers IOP by stimulating the ciliary body and the uveoscleral pathway, a route of aqueous outflow, without destructive effects. The SubCyclo probe is available on Quantel’s Supra 810 laser and based on SubLiminal™ proprietary technology.

SubCyclo preserves the structures of the ciliary body and improves the uveoscleral outflow. Because it is not destructive, it can be used earlier in the disease process for patients with open-angle and closure-angle glaucoma instead of for only refractory cases, and it is repeatable if needed. What’s more, this is a fast, easy procedure that we can perform with local anesthesia in 2 minutes.

Dr. Nassima Benhatchi, Hôpital Saint Joseph, Paris, France

We are delighted to bring this breakthrough, non-destructive treatment to millions of glaucoma sufferers. The ability to lower IOP safely, with the added advantages of speed and ease for patients and surgeons alike, makes this a very exciting advance in treatment of glaucoma.

Additional information on the SubCyclo procedure with 810nm Subliminal technology will be available during WGC 2017 in exhibit booth #1004.

For more information about Vitra 810, visit our website for healthcare professionnals:

The information collected through this form is recorded and transmitted to the relevant LUMIBIRD MEDICAL departments and enables us to send you any reply to a request via the contact form. The legal basis for the processing is consent. The data collected are kept for 3 years in digital format and are only transmitted to LUMIBIRD MEDICAL’s internal departments as well as to our distributors and subsidiaries. You have a right to access, rectify, contest, limit the processing of and erase data. For more information on the use of your data and your rights resulting from the amended French Data Protection Act and the GDPR, please consult our data protection policy or contact our Data Protection Officer at rgpd@lumibirdmedical.com.
For more informations on how Quantel Medical uses your data, please see our Terms and conditions.